Your browser doesn't support javascript.
Treating COVID-19: are we missing out the window of opportunity?
Sundararaj Stanleyraj, Jeremiah; Sethuraman, Nandini; Gupta, Rajesh; Thiruvoth, Sohanlal; Gupta, Manisha; Ryo, Akihide.
  • Sundararaj Stanleyraj J; Department of Microbiology, Yokohama City University School of Medicine, Kanagawa, Japan.
  • Sethuraman N; Department of Microbiology, Apollo Hospitals, Chennai, India.
  • Gupta R; Department of Medicine, Kuwait Hospital, Sharjah, United Arab Emirates.
  • Thiruvoth S; Department of Infection Control, Kuwait Hospital, Sharjah, United Arab Emirates.
  • Gupta M; Department of Microbiology, Super Specialty Cancer Institute and Hospital, Lucknow, India.
  • Ryo A; Department of Microbiology, Yokohama City University School of Medicine, Kanagawa, Japan.
J Antimicrob Chemother ; 76(2): 283-285, 2021 01 19.
Article in English | MEDLINE | ID: covidwho-889571
ABSTRACT
Severe COVID-19 is a biphasic illness, with an initial viral replication phase, followed by a cascade of inflammatory events. Progression to severe disease is predominantly a function of the inflammatory cascade, rather than viral replication per se. This understanding can be effectively translated to changing our approach in managing the disease. The natural course of disease offers us separate windows of specific time intervals to administer either antiviral or immunomodulatory therapy. Instituting the right attack at the right time would maximize the benefit of treatment. This concept must also be factored into studies that assess the efficacy of antivirals and immunomodulatory agents against COVID-19.
Subject(s)

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Immunomodulation / Time-to-Treatment / COVID-19 / Immunosuppressive Agents Limits: Humans Language: English Journal: J Antimicrob Chemother Year: 2021 Document Type: Article Affiliation country: Jac

Full text: Available Collection: International databases Database: MEDLINE Main subject: Antiviral Agents / Immunomodulation / Time-to-Treatment / COVID-19 / Immunosuppressive Agents Limits: Humans Language: English Journal: J Antimicrob Chemother Year: 2021 Document Type: Article Affiliation country: Jac